Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 10 December 2025 - 12 December 2025

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 (+1.80%) and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2 Note on timing: Saturday, Dec. 13, 2025 is a weekend, so U.S. stock markets
12 December 2025
··
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in Europe, and a steady stream of Wall Street price-target updates. As of 17:07 UTC (midday New York trading), MRK shares were at $99.69, up $0.68 (+0.69%) on the session. Merck stock price: where MRK stands on Dec. 12, 2025 MRK enters the final stretch of 2025 after a solid two-day run earlier in the week. On Thursday, Dec. 11, Merck
12 December 2025
···
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil) nasal spray , aimed at treating paroxysmal supraventricular tachycardia (PSVT) . The regulatory catalyst arrives after a volatile year that included an FDA Complete Response Letter (CRL) earlier in 2025, followed by the FDA’s acceptance of Milestone’s resubmission and a new target action date set for mid-December.GlobeNewswire+ 2GlobeNewswire+ 2 In the market, MIST shares closed at $2.95 on Dec. 11
12 December 2025
·
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY) is back in the spotlight on December 12, 2025, as the market digests a rapid sequence of obesity-pipeline headlines—alongside new questions about regulatory process, manufacturing scale-up, and what “priced for perfection” really means for one of healthcare’s most valuable companies. As of the latest quote available Friday, LLY traded around $1,009 per share, modestly higher on the day. Below is
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day, after swinging between an intraday high above $1,030 and a low just under $990.Investing.com+1 Late in the session and into after‑hours trading, the stock hovered slightly above the close near $1,009, according to real‑time data. The move leaves LLY only
11 December 2025
···
Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Date: December 11, 2025 Centessa Pharmaceuticals plc (NASDAQ: CNTA) is back in the spotlight after a major leadership announcement and a sharp intraday pullback in its share price. On December 11, 2025, the company unveiled a CEO transition that will take effect at the start of 2026, just as its orexin program heads toward pivotal studies.GlobeNewswire+1 Shares of Centessa traded around the high‑$20s on Thursday afternoon, down meaningfully on the day following the news. Earlier in the session, financial data service GuruFocus flagged an 8.4% drop to roughly $27 per share, underscoring how sensitive the stock remains to shifts in
11 December 2025
··
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11
11 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1 By late afternoon, Immunovant stock was trading around $25.75, up roughly 9% on the day, with an intraday range between $22.03 and $25.87, giving the company a market value of about $4 billion.Stock Titan That upbeat finish came despite an initial sell‑off; one early report noted shares dropped around 7%
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2 At the same time, the stock is still trading below its early‑October high, and investors are weighing Humira’s ongoing decline, softness in aesthetics, and regulatory risk against that growth story. Here’s a detailed look
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

On November 21, 2025, Eli Lilly and Company (NYSE: LLY) became the first pharmaceutical group ever to cross a $1 trillion market value, lifted by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound.Reuters+2Financial Times+2 Since then, investors have been digesting that historic moment alongside a fresh wave of drug data, a multibillion‑dollar manufacturing build‑out in Alabama, and a drumbeat of new analyst forecasts. Here’s a detailed, news‑driven look at where Eli Lilly stock stands today and what the latest information since 11/21/2025 suggests about its 2026 outlook. Eli Lilly (LLY) Stock Snapshot as of December 11, 2025
11 December 2025
·
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05 a.m. ET on Thursday, December 11, real‑time feeds put Pfizer stock near $25.78, roughly flat versus Wednesday’s close of $25.78 after a 1.78% gain in the prior session.StockAnalysis+1 The stock has traded between $20.92 and $27.69 over the past 12 months, and daily volume on Wednesday was around 43–44 million shares, close to its recent average.Investing.com+1 Despite its recent rebound,
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors alike. CoinCentral Today’s move in PFE is being driven by a cluster of fresh catalysts: Below is a detailed, news‑driven look at Pfizer stock today — including the latest news, forecasts and analysis relevant to 10 December 2025. 1. PFE
10 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12 months, OLMA’s share price has climbed from below $3 to nearly $30, according to Danelfin and CoinCodex ranges, reflecting a more than tenfold move at the extremes. Danelfin AI+1 Today’s spike is not a random move. It’s being driven by a cluster of catalysts that all hit investors’ screens at once: positive read‑through from a Roche breast cancer drug trial,
10 December 2025
·
Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. (NYSE: MRK) stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow is dominated by dividend chatter, options “whale” activity, new institutional ownership disclosures, and fresh signs that competition to flagship cancer drug Keytruda is getting real. This article summarizes the key developments around MRK as of December 10, 2025, including stock performance, Wall Street forecasts, institutional and options flows, and the latest strategic and pipeline updates. MRK stock performance today: modest
10 December 2025
·
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Updated: December 10, 2025 Johnson & Johnson (NYSE: JNJ) is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation. As of late trading on December 10, 2025, JNJ changes hands around $203–204 per share, up roughly 1.9% on the day, with an intraday high just above $204 and a low near $200. The stock has rallied roughly 38–41% year to date, handily beating many healthcare peers and broader indexes. Nasdaq+1 Today’s move comes as investors digest fresh Phase 3 cancer data, continued buying (and some selling) by institutional
10 December 2025
···
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda and the broader pipeline. As of late trading on December 10, 2025, Merck stock changes hands around $97.27, up slightly on the day after yesterday’s pullback. MarketWatch+1 Over roughly the past month, shares have climbed about 20%, helped by positive trial results and optimism around newer products like Winrevair. Finviz This article walks through the latest news from December 10,
10 December 2025
···
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk stock is having a very noisy December 10, 2025. American depositary shares of Novo Nordisk A/S (ticker NVO) recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity pipeline updates, an important downgrade from Argus, and increasingly loud questions about whether the GLP‑1 champion can hold its crown. This is exactly the kind of setup that confuses the daylights out of investors: bullish long‑term story, ugly short‑term chart,
10 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2 Against that backdrop, investors are trying to decide whether TEVA is simply “priced for the pivot” or
10 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 Key takeaways LLY stock today: price, performance and valuation snapshot As of mid‑day trading on December 10, 2025, Eli Lilly (NYSE: LLY) is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters Year to date, Reuters reports that LLY shares are up more than
10 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the day, implying a market capitalization of about $78–80 million.Simply Wall St That price sits near the low end of its 12‑month range of roughly $0.25 to $3.00, with the share price still down more than 70% over the past year
10 December 2025
··
1 … 22 23 24 25 26 … 34

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop